A-Ring reduced 17β-hydroxymethyl-13-ene metabolites for further extension of long-term detectability of 17-methyl steroids

Code: 20A06MP 

Since the detection of the latest long-term metabolite of metandienone a lot of effort is put in the uncoverage of similar metabolites with 17β-hydroxymethyl-17α-methyl-13-ene structure for long-term detection of other 17-methyl steroids. The closely related 4-chlorometandienone (Oral Turinabol, DHCMT) was found to be excreted as analogous metabolites, with A-ring reduced metabolites being even longer detectable.

Thus, in the current project we aim to investigate the excretion of metandienone with special respect to A-ring reduced metabolites as well. Their integration in doping control analysis may further extend the detection window of a misuse of metandienone and open new possibilities to catch cheaters that adjusted their habits to experiences after the integration of 17β-hydroxymethyl-17α-methylandrosta-1,4,13-triene-3-one into routine screening. Deduced from DHCMT metabolism, it is expected that also after metandienone administration a potentially further increased detection window may be achieved from screening for the analogue metabolite 17β-hydroxymethyl-17α-methyl-18-norandrost-13-en-3-ol.